Compare Gigacloud Technology Inc (GCT) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Johnson & Johnson — how do they compare? Gigacloud Technology Inc trades at $57.25 (market cap $2.02B), while Johnson & Johnson trades at $260.79 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 306× Gigacloud Technology Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Johnson & Johnson for 129 Days on average.
| GCT | JNJ | |
|---|---|---|
Market Cap | $2.02B | $618.09B |
Volume | 1,020,985 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $56.42 | $278.43 |
52-Week Low | $25.46 | $186.00 |
Typical Hold Time | 21 Days | 129 Days |
Enterprise Value | $2.14B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.02, up 1.89% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid profitability with 10.65% net margins and robust ROE of 32.34%. Recent news highlights institutional interest and European expansion driving growth.
Outlook remains positive with analyst consensus favoring buys (66.7%) and revenue projected to grow to $1.5B in 2026. Key risks include insider selling and competitive pressures in consumer discretionary sector. The stock trades at reasonable valuation multiples (P/E 13.44) with upside potential to consensus target of $32.50.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
